Highlights in acute lymphoblastic leukemia (ALL), presented ... BLIN improved outcomes for children with standard-risk B-cell ALL (B-ALL) at average or higher risk for relapse.

9 in Pediatric Blood & Cancer. Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR ...

Opens in a new tab or window SAN DIEGO -- Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without disease recurrence when they received the ...

THURSDAY, Dec. 12, 2024 (HealthDay News) -- For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high risk for relapse, adding blinatumomab ...

Hematologist-oncologists are doctors who specialize in treating blood cancers such as acute lymphoblastic leukemia (ALL ... makes too many white blood cells, leading to extreme tiredness ...

EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL).

The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the ...

for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Approval was based on results from the ...

HealthDay News — For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T ...

Venetoclax is under clinical development by AbbVie and currently in Phase II for Refractory Acute Myeloid Leukemia.

Chronic lymphocytic leukemia-- or CLL-- is a type of cancer ... that something happens to change the genetic code inside your cells that make white blood cells. Normally, these cells help your ...

Acute lymphoblastic leukemia (ALL) is a malignancy of lymphoid blood cells characterized by the immature lymphocytic ...